Michael Greenwood

Feature Writer

B.Sc. Chemistry, M.Sc. Drug Design and Discovery

Michael graduated from the University of Salford with a PhD in Biochemistry in 2023, and has keen research interests towards nanotechnology and its application to biological systems. Michael has written on a wide range of science communication and news topics within the life sciences and related fields since 2019, and engages extensively with current developments in journal publications.

Articles from Michael

Engineered T cells prevent translational shutdown in SARS-CoV-2 infected cells

In a paper recently uploaded to the preprint server bioRxiv* by Schamel et al. (June 25th, 2021) engineered T cells against SARS-CoV-2 are tested against a range of cells in vitro, finding that the treatment could be used to restore cellular immune function and suppress SARS-CoV-2.

1 Jul 2021

Antibody development against SARS-CoV-2 following Moderna vaccine

In a paper recently uploaded to the preprint server medRxiv* by Belda et al. (June 27th, 2021) two seroconversion panels containing the sera of individuals that received the Moderna (mRNA-1273) vaccine are compared, and the impact on neutralizing IgG antibody titers in these individuals is analyzed.

30 Jun 2021

How does dexamethasone therapy work in severe COVID-19?

The possible mechanisms that result in dexamethasone being an effective drug against severe SARS-CoV-2 infection are investigated in a new study. The paper’s authors advance the hypothesis that SARS-CoV-2 infection induces cell-specific insensitivity to glucocorticoids, possibly as an unintentional result of the viral replication cycle.

29 Jun 2021

Cationic peptides inhibit SARS-CoV-2 cell entry

In a paper recently published in Pathogens, in silico affinity studies by researchers at the University of Illinois, USA, reveal several potential peptide binding sites required for HS-spike protein and ACE2-spike protein bond formation, and synthesis of suitable peptide inhibitors reveals impaired SARS-CoV-2 cell entry.

29 Jun 2021

Nanotechnology and the fight against COVID-19

In a review paper published in the open-access MDPI journal Viruses, a team of researchers explored the potential of nanotechnology to alleviate the current and future coronavirus burden. The team focused on its potential role in the detection, diagnosis, protection, and treatment of SARS-CoV-2 infection.

29 Jun 2021

Strategies against the development of SARS-CoV-2 vaccine escape mutants

In a recent paper the impact of a number of vaccination strategies is assessed with regards to the probability of inducing a SARS-CoV-2 vaccine escape mutants.

21 Jun 2021

Age ascending COVID-19 vaccination could be a better option

A paper has been uploaded to the preprint server medRxiv*, allowing a comparison between demographics concerning the infectiousness of SARS-CoV-2.

21 Jun 2021

Alarming COVID study indicates long-term loss of gray matter and other brain tissue

In a research paper recently uploaded to the preprint server medRxiv* by Prof. Gwenaëlle Douaud et al. (June 15th, 2021), participants that had taken part in a brain study prior to the onset of the COVID-19 pandemic were invited back for a series of follow-up tests, revealing significant losses of grey matter surrounding the olfactory and gustatory system in those that had been infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2).

18 Jun 2021

Potent antibodies against SARS-CoV-2 can be produced without T follicular helper cells, suggests study

It has been uncertain whether antibodies produced via this non-canonical pathway are protective against SARS-CoV-2. In a new study, recently released as a preprint on the bioRxiv*server, the neutralization potency of these antibodies is compared with those traditionally produced in germinal center-based antiviral responses.

15 Jun 2021

Researchers screen dual main protease-cathepsin L inhibitors against SARS-CoV-2

In a recent study released on the bioRxiv* preprint server, a selective dual inhibitor of MPRO and cathepsin L is described, producing synergistic results that suppress SARS-CoV-2 infection.

15 Jun 2021